The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Novel Tacrine−8-Hydroxyquinoline Hybrids as Multifunctional Agents for the Treatment of Alzheimer’s Disease, with Neuroprotective, Cholinergic, Antioxidant, and Copper-Complexing Properties
Open accessAbstract
Tacrine and PBT2 (an 8-hydroxyquinoline derivative) are well-known drugs that inhibit cholinesterases and decrease beta-amyloid (Abeta) levels by complexation of redox-active metals, respectively. In this work, novel tacrine-8-hydroxyquinoline hybrids have been designed, synthesized, and evaluated as potential multifunctional drugs for the treatment of Alzheimer's disease. At nano- and subnanomolar concentrations they inhibit human acetyl- and butyrylcholinesterase (AChE and BuChE), being more potent than tacrine. They also displace propidium iodide from the peripheral anionic site of AChE and thus could be able to inhibit Abeta aggregation promoted by AChE. They show better antioxidant properties than Trolox, the aromatic portion of vitamin E responsible for radical capture, and display neuroprotective properties against mitochondrial free radicals. In addition, they selectively complex Cu(II), show low cell toxicity, and could be able to penetrate the CNS, according to an in vitro blood-brain barrier model.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new and rapid colorimetric determination of acetylcholinesterase activity
Ellman, G. L., Courtney, K. D., Andres, V., & Featherstone, R. M. (1961) · Biochemical Pharmacology · doi:10.1016/0006-2952(61)90145-9 · Cited by 27,126
Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
Ou, B., Hampsch-Woodill, M., & Prior, R. L. (2001) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf010586o · Cited by 2,932
Binding constants: The measurement of molecular complex stability
(1987) · European Journal of Medicinal Chemistry · doi:10.1016/0223-5234(87)90280-7 · Cited by 1,779
Extending Applicability of the Oxygen Radical Absorbance Capacity (ORAC−Fluorescein) Assay
Dávalos, A., Gómez-Cordovés, C., & Bartolomé, B. (2004) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf0305231 · Cited by 1,207
High throughput artificial membrane permeability assay for blood–brain barrier
Di, L., Kerns, E. H., Fan, K., McConnell, O. J., & Carter, G. T. (2003) · European Journal of Medicinal Chemistry · doi:10.1016/s0223-5234(03)00012-6 · Cited by 1,195
Multi-target-Directed Ligands To Combat Neurodegenerative Diseases
Cavalli, A., Bolognesi, M. L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., & Melchiorre, C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7009364 · Cited by 1,152
Ritchie, C. W., Bush, A. I., Mackinnon, A., Macfarlane, S., Mastwyk, M., MacGregor, L., Kiers, L., Cherny, R., Li, Q.-X., Tammer, A., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1685 · Cited by 988
Hepatotoxic Effects of Tacrine Administration in Patients With Alzheimer's Disease
Watkins, P. B. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510370044030 · Cited by 829
Intramuscular desferrioxamine in patients with Alzheimer's disease
MCLACHLAN, D. (1991) · The Lancet · doi:10.1016/0140-6736(91)92978-b · Cited by 764
Cu(II) Potentiation of Alzheimer Aβ Neurotoxicity
Huang, X., Cuajungco, M. P., Atwood, C. S., Hartshorn, M. A., Tyndall, J. D. A., Hanson, G. R., Stokes, K. C., Leopold, M., Multhaup, G., Goldstein, L. E., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.52.37111 · Cited by 762
Lannfelt, L., Blennow, K., Zetterberg, H., Batsman, S., Ames, D., Harrison, J., Masters, C. L., Targum, S., Bush, A. I., Murdoch, R., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70167-4 · Cited by 725
Adlard, P. A., Cherny, R. A., Finkelstein, D. I., Gautier, E., Robb, E., Cortes, M., Volitakis, I., Liu, X., Smith, J. P., Perez, K., et al. (2008) · Neuron · doi:10.1016/j.neuron.2008.06.018 · Cited by 672
Targeting acetylcholinesterase and butyrylcholinesterase in dementia
Lane, R. M., Potkin, S. G., & Enz, A. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005833 · Cited by 654
The redox chemistry of the Alzheimer's disease amyloid β peptide
Smith, D. G., Cappai, R., & Barnham, K. J. (2007) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2007.02.002 · Cited by 608
Oxidative stress in the progression of Alzheimer disease in the frontal cortex
Ansari, M. A., & Scheff, S. W. (2010) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181cb5af4 · Cited by 605
Cygler, M., Schrag, J. D., Sussman, J. L., Harel, M., Silman, I., Gentry, M. K., & Doctor, B. P. (1993) · Protein Science · doi:10.1002/pro.5560020309 · Cited by 565
Dong, J., Atwood, C. S., Anderson, V. E., Siedlak, S. L., Smith, M. A., Perry, G., & Carey, P. R. (2003) · Biochemistry · doi:10.1021/bi0272151 · Cited by 562
Redox‐Active Metals, Oxidative Stress, and Alzheimer's Disease Pathology
HUANG, X., MOIR, R. D., TANZI, R. E., BUSH, A. I., & ROGERS, J. T. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1306.012 · Cited by 425
A Structural Motif of Acetylcholinesterase That Promotes Amyloid β-Peptide Fibril Formation
De Ferrari, G. V., Canales, M. A., Shin, I., Weiner, L. M., Silman, I., & Inestrosa, N. C. (2001) · Biochemistry · doi:10.1021/bi0101392 · Cited by 413
PBT2 Rapidly Improves Cognition in Alzheimer's Disease: Additional Phase II Analyses
Faux, N. G., Ritchie, C. W., Gunn, A., Rembach, A., Tsatsanis, A., Bedo, J., Harrison, J., Lannfelt, L., Blennow, K., Zetterberg, H., et al. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1390 · Cited by 405
Copper Mediates Dityrosine Cross-Linking of Alzheimer's Amyloid-β
Atwood, C. S., Perry, G., Zeng, H., Kato, Y., Jones, W. D., Ling, K.-Q., Huang, X., Moir, R. D., Wang, D., Sayre, L. M., et al. (2004) · Biochemistry · doi:10.1021/bi0358824 · Cited by 371
Taylor, P., & Lappi, S. (1975) · Biochemistry · doi:10.1021/bi00680a029 · Cited by 364
Ackermann, T. (1987) · Berichte der Bunsengesellschaft für physikalische Chemie · doi:10.1002/bbpc.19870911223 · Cited by 349
Alvarez, A., Opazo, C., Alarcón, R., Garrido, J., & Inestrosa, N. C. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.1245 · Cited by 306
Oxidative Stress in Diabetes and Alzheimer's Disease
Reddy, V. P., Zhu, X., Perry, G., & Smith, M. A. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-1013 · Cited by 280
Drug Development Based on the Metals Hypothesis of Alzheimer's Disease
Bush, A. I. (2008) · Journal of Alzheimer's Disease · doi:10.3233/jad-2008-15208 · Cited by 267
Rodríguez-Franco, M. I., Fernández-Bachiller, M. I., Pérez, C., Hernández-Ledesma, B., & Bartolomé, B. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm050746d · Cited by 248
Self-citationRational Approach To Discover Multipotent Anti-Alzheimer Drugs
Rosini, M., Andrisano, V., Bartolini, M., Bolognesi, M. L., Hrelia, P., Minarini, A., Tarozzi, A., & Melchiorre, C. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049112h · Cited by 226
Targeting acetylcholinesterase to treat neurodegeneration
Holzgrabe, U., Kapková, P., Alptüzün, V., Scheiber, J., & Kugelmann, E. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.2.161 · Cited by 217
Cholinesterase Inhibitors and Beyond
Pepeu, G., & Giovannini, M. (2009) · Current Alzheimer Research · doi:10.2174/156720509787602861 · Cited by 209
Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors
Castro, A., & Martinez, A. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206778792985 · Cited by 207
Camps, P., Formosa, X., Galdeano, C., Muñoz-Torrero, D., Ramírez, L., Gómez, E., Isambert, N., Lavilla, R., Badia, A., Clos, M. V., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900859q · Cited by 173
Self-citationSipos, I., Tretter, L., & Adam‐Vizi, V. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01513.x · Cited by 167
Fernández‐Bachiller, M. I., Pérez, C., Campillo, N. E., Páez, J. A., González‐Muñoz, G. C., Usán, P., García‐Palomero, E., López, M. G., Villarroya, M., García, A. G., et al. (2009) · ChemMedChem · doi:10.1002/cmdc.200800414 · Cited by 159
Self-citationAlzheimer Disease and the Role of Free Radicals in the Pathogenesis of the Disease
Perry, G. L., Moreira, P. I., Santos, M. S., Oliveira, C. R., Shenk, J. C., Nunomura, A., Smith, M. A., & Zhu, X. (2008) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152708783885156 · Cited by 155
Savini, L., Gaeta, A., Fattorusso, C., Catalanotti, B., Campiani, G., Chiasserini, L., Pellerano, C., Novellino, E., McKissic, D., & Saxena, A. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm0255668 · Cited by 148
d ‐penicillamine reduces serum oxidative stress in Alzheimer’s disease patients
Squitti, R., Rossini, P. M., Cassetta, E., Moffa, F., Pasqualetti, P., Cortesi, M., Colloca, A., Rossi, L. C., & Finazzi‐Agrò, A. (2002) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2002.00933.x · Cited by 145
Multipotent antioxidants: from screening to design
Zhang, H., Yang, D., & Tang, G.-Y. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.06.007 · Cited by 137
Marco, J. L., Leon, R. M., Ríos, C. D. L., Samadi, A., Bartolini, M., Andrisano, V., Huertas, Ó., Barril, X., Luque, F. J., Rodríguez-Franco, M. I., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801292b · Cited by 137
Self-citationBolognesi, M. L., Andrisano, V., Bartolini, M., Banzi, R., & Melchiorre, C. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049156q · Cited by 136
Carlier, P. R., Chow, E. S. ‐., Han, Y., Liu, J., Yazal, J. E., & Pang, Y. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm990224w · Cited by 129
Acetylcholinesterase-Aβ Complexes Are More Toxic than Aβ Fibrils in Rat Hippocampus
Reyes, A. E., Chacón, M. A., Dinamarca, M. C., Cerpa, W. F., Morgan, C., & Inestrosa, N. C. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63774-1 · Cited by 129
Bolognesi, M. L., Cavalli, A., & Melchiorre, C. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.10.042 · Cited by 126
All-transretinoic acid as a novel therapeutic strategy for Alzheimer’s disease
Lee, H. P., Casadesús, G., Zhu, X., Lee, H., Perry, G. L., Smith, M. A., Gustaw‐Rothenberg, K., & Lerner, A. J. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.86 · Cited by 124
Fang, L., Appenroth, D., Decker, M. W., Kiehntopf, M., Roegler, C., Deufel, T., Fleck, C., Peng, S., Zhang, Y., & Lehmann, J. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701491k · Cited by 116
Pavón, F. J., Bilbao, A., Hernández‐Folgado, L., Cippitelli, A., Jagerovic, N., Abellán, G., Rodríguez-Franco, M. I., Serrano, A., Macías, M., de Heras, R. G., et al. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.03.029 · Cited by 115
Self-citationArce, M. P., Rodrı́guez-Franco, M. I., González-Muñoz, G. C., Pérez, C., López, B., Villarroya, M., López, M. G., Garcı́a, A. G., & Conde, S. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900628z · Cited by 109
Self-citationOsseni, R., DEBBASCH, C., Christen, M. O., Rat, P., & Warnet, J. (1999) · Toxicology in Vitro · doi:10.1016/s0887-2333(99)00050-8 · Cited by 107
Structure-Function Implications in Alzheimers Disease: Effect of Aβ Oligomers at Central Synapses
Cerpa, W. F., Dinamarca, M. C., & Inestrosa, N. C. (2008) · Current Alzheimer Research · doi:10.2174/156720508784533321 · Cited by 100
Gu, F., Zhu, M., Shi, J., Hu, Y., & Zhao, Z. Y. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.05.050 · Cited by 85
An update on the pharmacology of galantamine
Villarroya, M., Garcı́a, A. G., Marco, J. L., & López, M. G. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.12.1987 · Cited by 79
Self-citationEmpirical evidence of neuroprotection by dual cholinesterase inhibition in Alzheimer??s disease
Venneri, A., McGeown, W. J., & Shanks, M. F. (2005) · Neuroreport · doi:10.1097/00001756-200502080-00006 · Cited by 64
Spuch, C., Antequera, D., Fernández‐Bachiller, M. I., Rodrı́guez-Franco, M. I., & Carro, E. (2009) · Neurotoxicity Research · doi:10.1007/s12640-009-9121-2 · Cited by 62
Self-citationGrossberg, G. T., Pejović, V., Miller, M. L., & Graham, S. M. (2009) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000200013 · Cited by 59
Cholinesterase inhibition: is there evidence for disease-modifying effects?
Shanks, M. F., Kivipelto, M., Bullock, R. A., & Lane, R. M. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903209332 · Cited by 58
Dogterom, P., Nagelkerke, J. F., & Mulder, G. J. (1988) · Biochemical Pharmacology · doi:10.1016/0006-2952(88)90356-5 · Cited by 50
Rodrı́guez-Franco, M. I., Fernández‐Bachiller, M. I., Pérez, C., Castro, A., & Martı́nez, A. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.07.019 · Cited by 50
Self-citationGarcía‐Palomero, E., Muñoz, P., Usán, P., Garcia, P., Delgado, E., de Austria, C., Valenzuela, R., Rubio, L., Medina, M., & Martı́nez, A. (2008) · Neurodegenerative Diseases · doi:10.1159/000113688 · Cited by 45
Treatment of Alzheimer’s disease in the long-term-care setting
Smith, D. A. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp070622 · Cited by 41
Agents Complexing Copper as a Therapeutic Strategy for the Treatment of Alzheimers Disease
Squitti, R., & Salustri, C. (2009) · Current Alzheimer Research · doi:10.2174/156720509790147133 · Cited by 35
Effects of cholinesterase inhibition on brain white matter volume in Alzheimer's disease
Venneri, A., & Lane, R. M. (2009) · Neuroreport · doi:10.1097/wnr.0b013e3283207d21 · Cited by 34
Ezoulin, M. J. M., Dong, C., Liu, Z., Li, J., Chen, H. Z., Heymans, F., Lelièvre, L. G., Ombetta, J., & Massicot, F. (2006) · Toxicology in Vitro · doi:10.1016/j.tiv.2006.01.002 · Cited by 33
Reviriego, F., Rodrı́guez-Franco, M. I., Navarro, P., García‐España, E., Liu‐González, M., Verdejo, B., & Doménech‐Carbó, A. (2006) · Journal of the American Chemical Society · doi:10.1021/ja064657h · Cited by 32
Self-citationTherapeutic Treatment of Alzheimers Disease Using Metal Complexing Agents
Price, K. A., Crouch, P. J., & White, A. R. (2007) · Recent Patents on CNS Drug Discovery · doi:10.2174/157488907782411774 · Cited by 30
Cu (II ) Potentiation of Alzheimer Ab Neurotoxicity
Huang, X., Cuajungco, M. P., Atwood, C., Hartshorn, M. A., Tyndall, J. D. A., Hanson, G. R., Stokes, K. C., Leopold, M. C., Multhaup, G., Goldstein, L. E., et al. (1999) · Cited by 28
Cited by
New Acetylcholinesterase Inhibitors for Alzheimer's Disease
Mehta, M., Adem, A., & Sabbagh, M. (2012) · International Journal of Alzheimer's Disease · doi:10.1155/2012/728983 · Cited by 436
Sharma, P., Srivastava, P., Seth, A., Tripathi, P. N., Banerjee, A. G., & Shrivastava, S. K. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.12.006 · Cited by 331
Guzior, N., Wi.eckowska, A., Panek, D., & Malawska, B. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666141106122628 · Cited by 323
Fernández-Bachiller, M. I., Pérez, C., Monjas, L., Rademann, J., & Rodríguez-Franco, M. I. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201460y · Cited by 268
Self-citationCombination Drug Therapy for the Management of Alzheimer’s Disease
Kabir, M. T., Uddin, M. S., Mamun, A. A., Jeandet, P., Aleya, L., Mansouri, R. A., Ashraf, G. M., Mathew, B., Bin-Jumah, M. N., & Abdel-Daim, M. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093272 · Cited by 217
Metadata
- Authors
- Fernández-Bachiller, M. I., Pérez, C., González-Muñoz, G. C., Conde, S., López, M. G., Villarroya, M., García, A. G., & Rodríguez-Franco, M. I.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2010-06-14
- Volume
- 53
- Issue
- 13
- Pages
- 4927-4937
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2070075494
- Cited by
- 268
- References
- 66
- FWCI
- 10.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.